High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt, Mohammed Lamorde, Saye Khoo, Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt, Mohammed Lamorde, Saye Khoo

Abstract

Background: Efavirenz-related nervous system or psychiatric adverse drug reactions (ADRs) are conventionally reported to resolve soon after initiation, with incidence of dizziness at 8.5% in large clinical trials. Patients of black ethnicity are genetically at greater risk of elevated efavirenz exposure, which has been linked to nervous system toxicity.

Patients and methods: The current data derive from a prospective longitudinal observational study of adult HIV-positive outpatients taking current antiretrovirals, at three diverse clinics in central Uganda. As part of an interview about medicine use, patients were asked by trained pharmacy technicians to detail current side effects and to rate their severity on a simple visual analogue scale (1-10). Details of the reported ADRs were verified by case note review. Severity and causality of ADRs were rated by the study team using validated tools.

Results: A total of 300 patients taking efavirenz were analysed. Of these, 108 (36%, 95% CI 30.6%-41.7%) were affected by persisting nervous system/psychiatric ADRs (median duration 22 months). Dizziness affected 27.3% (95% CI 22.4%-32.8%) of patients taking efavirenz. Severity of the ADRs was rated by patients at ≥5/10 in 76 (58.5%) cases. In 95 (86%) cases, there was no record of the ADRs in the clinical notes.

Conclusions: Strategies are needed to identify and prioritize patients urgently with persisting efavirenz neurotoxicity for a switch to newer regimens as they become available.

Figures

Figure 1.
Figure 1.
(a) Patient-rated severity of efavirenz-associated NSD/PD ADRs (VAS 1–10). ADRs reported: n = 130, by 108 patients. Severity was reported by patients in 122 cases. (b) Study team severity rating of NSD/PD ADRs related to efavirenz (DAIDS classification).

References

    1. Gounden V, van Niekerk C, Snyman T. et al. Presence of the CYP2B6 516G>T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010; 7: 32.
    1. Stohr W, Back D, Dunn D. et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675–85.
    1. Jamshidi Y, Moreton M, McKeown DA. et al. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 2010; 65: 2614–9.
    1. Dickinson L, Amin J, Else L. et al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naïve HIV-Infected patients at 96 weeks: results of the ENCORE1 Study. Clin Pharmacokinet 2016; 55: 861–73.
    1. Carey D, Puls R, Amin J. et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15: 793–802.
    1. Ministry of Health (Uganda). Consolidated Guidelines for Prevention and Treatment of HIV in Uganda 2016. .
    1. UK Research and Innovation. Prevalence of, and Harm Caused by Medication Error in Antiretroviral Programs in Uganda .
    1. Gallagher RM, Kirkham JJ, Mason JR. et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One 2011; 6: e28096.
    1. US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. .
    1. Bristol-Myers Squibb Pharmaceutical Limited. Sustiva (Efavirenz) 600 mg Film-Coated Tablets, UK Summary of Product Characteristics 2016. .
    1. Ford N, Shubber Z, Pozniak A. et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr 2015; 69: 422–9.
    1. Gaida R, Truter I, Grobler C. et al. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Rev Anti Infect Ther 2016; 14: 377–88.
    1. Clifford DB, Evans S, Yang Y. et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009; 10: 343–55.
    1. Leutscher PD, Stecher C, Storgaard M. et al. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis 2013; 45: 645–51.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir